EPHA2 and Familial prostate cancer: KIAA1199 further reduces the expression of Sema3A, increases the expression of VE-cadherin and phosphorylated EphA2, and enhances angiogenesis and vasculogenic mimicry in prostate cancer by enhancing hyaluronic acid-mediated VEGFA signaling (49).